CN106237023A - A kind of pharmaceutical composition treating gastritis and preparation method thereof - Google Patents
A kind of pharmaceutical composition treating gastritis and preparation method thereof Download PDFInfo
- Publication number
- CN106237023A CN106237023A CN201610821322.1A CN201610821322A CN106237023A CN 106237023 A CN106237023 A CN 106237023A CN 201610821322 A CN201610821322 A CN 201610821322A CN 106237023 A CN106237023 A CN 106237023A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- fine powder
- standby
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The present invention relates to a kind of pharmaceutical composition treating gastritis and preparation method thereof, this pharmaceutical composition is made up of the medicine of following weight portion: Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae, Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae, is made by techniques such as decoction, alcohol extractions；Pharmaceutical composition of the present invention points out pharmaceutical composition of the present invention to have the effects such as sterilization, antiinflammatory, analgesia by pharmacodynamics test；By acute toxicity test, long term toxicity test result shows: without obvious toxic reaction under this experiment condition；Compared with existing commercial preparation, effect of the present invention is obvious, rapid-action, has no side effect；Treating gastritis sufferer 900 example by clinical trial, total effective rate reaches 98%, and effect is obvious, and does not finds untoward reaction and toxic and side effects, illustrates that pharmaceutical composition of the present invention is evident in efficacy in terms for the treatment of gastritis, has good promotional value.
Description
Technical field
The present invention relates to field of medicine invention, be specifically related to a kind of pharmaceutical composition treating gastritis and preparation method thereof.
Background technology
Gastritis refers to that being caused gastric mucosa to be inflamed by various factors sexually revises, irregular at diet, works and rests erratic
Crowd is the most occurred frequently.Including acute gastritis (acute phlegmonous gastritis, acute erosive gastritis, acute simple gastritis, acute corruption
Erosion property gastritis), chronic gastritis (chronic superficial gastritis, atrophic gastritis, chronic erosive gastritis), postoperative reflux stomach
Inflammation, bile reflux gastritis, electric refrigerator gastritis, giant hypertrophy gastritis etc..Acute gastritis morbidity is hurried, and the lighter only has appetite not
Shake, suffer from abdominal pain, Nausea and vomiting；Severe patient may occur in which hematemesis, melena, dehydration, electrolyte and acid base imbalance, has antibacterial to infect
Person is often accompanied by systemic toxicity profiles symptom；2, chronic gastritis lacks specific symptom, and the weight of symptom is with the lesion degree of gastric mucosa also
Non-uniform.The normal non-evident sympton of Most patients or have indigestion symptom in various degree, as upper abdomen dull pain, loss of appetite,
Post-prandial fullness, acid regurgitation etc.；3, patients with atrophic gastritis can have anemia, become thin, the symptom such as glossitis, diarrhoea, rotten with mucosa individually
Rotten patient's upper abdominal pain is more apparent, and can have hemorrhage.Acute gastritis can symptomatic treatment, regrettably chronic gastritis does not has at present
Specially good effect effect treatment, it is the most urgent for therefore researching and developing a kind of medicine effecting a radical cure chronic gastritis.
The present inventor, in order to solve the problems referred to above, have developed a kind of new drug.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating gastritis.
It is a further object of the present invention to provide the preparation method of a kind of pharmaceutical composition treating gastritis.
The present invention provides a kind of pharmaceutical composition treating gastritis, and this pharmaceutical composition is by the medicine system of following weight portion
Become: Semen Iridis 20-60 part, Chinese honey locust (fruit) 10-50 part, Fructus Gleditsiae Abnormalis 10-45 part, Dioscorea septemloba Thunb. 15-60 part, Herba Siegesbeckiae 10-55 part, Rhizoma Bolbostematis
Female 10-45 part, Radix Serratulae Chinensis 10-55 part, Folium Symplocoris Caudatae 12-45 part, Radix Isatidis 10-45 part, hieracioides 15-50 part, Cortex Phellodendri 20-70
Part, Radix Glycyrrhizae 20-60 part.
Preferably, pharmaceutical composition of the present invention is made up of the medicine of following weight portion: Semen Iridis 25-55 part, big
Fructus Gleditsia 15-45 part, Fructus Gleditsiae Abnormalis 15-40 part, Dioscorea septemloba Thunb. 20-55 part, Herba Siegesbeckiae 15-50 part, Rhizoma Bolbostematis 15-40 part, Radix Serratulae Chinensis 15-
50 parts, Folium Symplocoris Caudatae 15-42 part, Radix Isatidis 15-40 part, hieracioides 20-45 part, Cortex Phellodendri 25-65 part, Radix Glycyrrhizae 25-55 part.
It is further preferred that pharmaceutical composition of the present invention is made up of the medicine of following weight portion: Semen Iridis 30-50
Part, Chinese honey locust (fruit) 20-40 part, Fructus Gleditsiae Abnormalis 20-35 part, Dioscorea septemloba Thunb. 28-47 part, Herba Siegesbeckiae 20-45 part, Rhizoma Bolbostematis 20-35 part, extensively rise
Fiber crops 20-45 part, Folium Symplocoris Caudatae 20-37 part, Radix Isatidis 20-35 part, hieracioides 25-40 part, Cortex Phellodendri 33-57 part, Radix Glycyrrhizae 30-50 part.
Further preferred, pharmaceutical composition of the present invention is made up of the medicine of following weight portion: Semen Iridis 35-
45 parts, Chinese honey locust (fruit) 25-35 part, Fructus Gleditsiae Abnormalis 23-32 part, Dioscorea septemloba Thunb. 33-42 part, Herba Siegesbeckiae 25-40 part, Rhizoma Bolbostematis 23-32 part, wide
Rhizoma Cimicifugae 26-39 part, Folium Symplocoris Caudatae 23-33 part, Radix Isatidis 23-32 part, hieracioides 29-37 part, Cortex Phellodendri 40-50 part, Radix Glycyrrhizae 35-45
Part.
Further preferred, pharmaceutical composition of the present invention is made up of the medicine of following weight portion: Semen Iridis 40
Part, Chinese honey locust (fruit) 30 parts, Fructus Gleditsiae Abnormalis 28 parts, Dioscorea septemloba Thunb. 38 parts, Herba Siegesbeckiae 32 parts, Rhizoma Bolbostematis 27 parts, Radix Serratulae Chinensis 32 parts, Folium Symplocoris Caudatae 28
Part, Radix Isatidis 28 parts, hieracioides 33 parts, Cortex Phellodendri 45 parts, 40 parts of Radix Glycyrrhizae.
Pharmaceutical composition of the present invention is possibly together with pharmaceutically acceptable carrier or diluent.
Pharmaceutical composition of the present invention is solid preparation or liquid preparation, described solid preparation be tablet, capsule,
Granule or pill；Described liquid preparation is oral liquid.
Pharmaceutical composition preparation method of the present invention comprises the following steps: by Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, silk floss
Bi, Herba Siegesbeckiae, Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae pulverize and sieve, and pharmaceutically can connect
The carrier being subject to or diluent mix homogeneously, be prepared as preparation.
Pharmaceutical composition preparation method of the present invention comprises the following steps:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added the heating of 3-7 times amount water and decoct 1-3 hour, mistake
Filter, filtrate concentrate drying, it is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae add the water of 2-5 times amount, and heating is decocted
Boil 2 hours, filter, filtrate concentrate drying, be ground into fine powder, standby；Soak with ethanol 8-13 that filtering residue adds 2-5 times amount 75% is little
Time, filter, filtrate concentrate drying, be ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add pharmaceutically acceptable carrier or diluent mix homogeneously, make preparation.
Preferably, pharmaceutical composition preparation method of the present invention comprises the following steps:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add pharmaceutically acceptable carrier or diluent mix homogeneously, make preparation.
Described parts by weight can be unit of weight known to the field of medicaments such as μ g, mg, g, kg.
The implication of times amount refers to the weight ratio of medical material.
Described pharmaceutically acceptable carrier or diluent refer to the pharmaceutical carrier that pharmaceutical field is conventional, selected from filler,
One or more in binding agent, disintegrating agent, lubricant, surfactant or correctives.
Wherein said filler is selected from starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline Cellulose or Portugal
Grape sugar etc.；
Described binding agent is selected from cellulose derivative, alginate, gelatin or polyvinylpyrrolidone etc.；
Described disintegrating agent is selected from microcrystalline Cellulose, carboxymethyl starch sodium, polyvinylpyrrolidone, low substituted hydroxy-propyl fiber
Element or cross-linking sodium carboxymethyl cellulose；
Described lubricant is selected from stearic acid, Polyethylene Glycol, calcium carbonate, sodium bicarbonate, silicon dioxide, Pulvis Talci or stearic acid
Magnesium；
Described surfactant is selected from dodecylbenzene sodium sulfonate, stearic acid, Pluronic F68, fat
Fat acid Pyrusussuriensis is smooth or Polysorbate (tween) etc.；
Described correctives is selected from aspartame, Sucralose or saccharin sodium.
The pharmaceutical composition of the treatment gastritis that the present invention provides has the advantage that
Pharmaceutical composition of the present invention has the effect that 1, has infection of staphylococcus aureus mice significantly
Sterilization or inhibitory action；2, the mice capillary permeability increase that acetic acid causes is reduced；3, reduce what dimethylbenzene caused
Mice ear；Reduce the writhing number of times of acetic acid induced pain mice, point out pharmaceutical composition of the present invention to have sterilization, antiinflammatory, analgesia
Etc. effect.By acute toxicity test, long term toxicity test result shows: without obvious toxic reaction under this experiment condition.
Compared with existing commercial preparation, effect of the present invention is obvious, rapid-action, has no side effect；Gastritis sufferer is treated by clinical trial
900 examples, total effective rate reaches 98%, and effect is obvious, and does not finds untoward reaction and toxic and side effects, and drug regimen of the present invention is described
Thing is evident in efficacy in terms for the treatment of gastritis, has good promotional value.
Detailed description of the invention
Following example are used for illustrating the present invention, but are not limited to the scope of the present invention.
Embodiment 1
Prescription: Semen Iridis 20g, Chinese honey locust (fruit) 10g, Fructus Gleditsiae Abnormalis 10g, Dioscorea septemloba Thunb. 15g, Herba Siegesbeckiae 10g, Rhizoma Bolbostematis 10g, extensively rise
Fiber crops 10g, Folium Symplocoris Caudatae 12g, Radix Isatidis 10g, hieracioides 15g, Cortex Phellodendri 20g, Radix Glycyrrhizae 20g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 3 times amount water heating and decoct 1-3 hour, filter,
Filtrate concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 2 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 8 hours of 2 times amount 75%, filters, filter
Liquid concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 2
Prescription: Semen Iridis 60g, Chinese honey locust (fruit) 50g, Fructus Gleditsiae Abnormalis 45g, Dioscorea septemloba Thunb. 60g, Herba Siegesbeckiae 55g, Rhizoma Bolbostematis 45g, extensively rise
Fiber crops 55g, Folium Symplocoris Caudatae 45g, Radix Isatidis 45g, hieracioides 50g, Cortex Phellodendri 70g, Radix Glycyrrhizae 60g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 7 times amount water heating and decoct 3 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 5 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 13 hours of 5 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/5, be dried, tabletting, obtain this
The tablet of application.
Embodiment 3
Prescription: Semen Iridis 25g, Chinese honey locust (fruit) 15g, Fructus Gleditsiae Abnormalis 15g, Dioscorea septemloba Thunb. 20g, Herba Siegesbeckiae 15g, Rhizoma Bolbostematis 15g, extensively rise
Fiber crops 15g, Folium Symplocoris Caudatae 15g, Radix Isatidis 15g, hieracioides 20g, Cortex Phellodendri 25g, Radix Glycyrrhizae 25g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 4 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 9 hours of 3 times amount 75%, filters, filter
Liquid concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 4
Prescription: Semen Iridis 55g, Chinese honey locust (fruit) 45g, Fructus Gleditsiae Abnormalis 40g, Dioscorea septemloba Thunb. 55g, Herba Siegesbeckiae 50g, Rhizoma Bolbostematis 40g, extensively rise
Fiber crops 50g, Folium Symplocoris Caudatae 42g, Radix Isatidis 40g, hieracioides 45g, Cortex Phellodendri 65g, Radix Glycyrrhizae 55g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 6 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 4 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 12 hours of 4 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/5, mixing, pelletize, be dried,
Granulate, obtains the granule of the application.
Embodiment 5
Prescription: Semen Iridis 30g, Chinese honey locust (fruit) 20g, Fructus Gleditsiae Abnormalis 20g, Dioscorea septemloba Thunb. 28g, Herba Siegesbeckiae 20g, Rhizoma Bolbostematis 20g, extensively rise
Fiber crops 20g, Folium Symplocoris Caudatae 20g, Radix Isatidis 20g, hieracioides 25g, Cortex Phellodendri 33g, Radix Glycyrrhizae 30g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 6
Prescription: Semen Iridis 50g, Chinese honey locust (fruit) 40g, Fructus Gleditsiae Abnormalis 35g, Dioscorea septemloba Thunb. 47g, Herba Siegesbeckiae 45g, Rhizoma Bolbostematis 35g, extensively rise
Fiber crops 45g, Folium Symplocoris Caudatae 37g, Radix Isatidis 35g, hieracioides 40g, Cortex Phellodendri 57g, Radix Glycyrrhizae 30-50g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 7
Prescription: Semen Iridis 35g, Chinese honey locust (fruit) 25g, Fructus Gleditsiae Abnormalis 23g, Dioscorea septemloba Thunb. 33g, Herba Siegesbeckiae 25g, Rhizoma Bolbostematis 23g, extensively rise
Fiber crops 26g, Folium Symplocoris Caudatae 23g, Radix Isatidis 23g, hieracioides 29g, Cortex Phellodendri 40g, Radix Glycyrrhizae 35g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 8
Prescription: Semen Iridis 45g, Chinese honey locust (fruit) 35g, Fructus Gleditsiae Abnormalis 32g, Dioscorea septemloba Thunb. 42g, Herba Siegesbeckiae 40g, Rhizoma Bolbostematis 32g, extensively rise
Fiber crops 39g, Folium Symplocoris Caudatae 33g, Radix Isatidis 32g, hieracioides 37g, Cortex Phellodendri 50g, Radix Glycyrrhizae 45g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
Embodiment 9
Prescription: Semen Iridis 40g, Chinese honey locust (fruit) 30g, Fructus Gleditsiae Abnormalis 28g, Dioscorea septemloba Thunb. 38g, Herba Siegesbeckiae 32g, Rhizoma Bolbostematis 27g, extensively rise
Fiber crops 32g, Folium Symplocoris Caudatae 28g, Radix Isatidis 28g, hieracioides 33g, Cortex Phellodendri 45g, Radix Glycyrrhizae 40g.
Preparation method:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added 5 times amount water heating and decoct 2 hours, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae are added the water of 3 times amount, heats decoction 2
Hour, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters,
Filtrate concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add the starch accounting for mix homogeneously fine powder weight 1/7, load capsule, make glue
Wafer.
In order to beneficial effects of the present invention is expanded on further, inventor has done pharmacodynamics test and clinical trial, the most such as
Under:
One, pharmacodynamics test and toxicological test
1, experiment material
(1) medicine: the pharmaceutical composition of the present invention (high dose group, middle dosage group, low dose group) used by experiment；Ah former times Lip river
Wei sheet；Aspirin；Have a stomachache peaceful granule；Nimesulide.
(2) Strain: influenza A virus A/PR/8/34, the anti-98-76 in Influenza B virus B/ capital.
(3) bacterial strain: reference culture: staphylococcus aureus (25923), escherichia coli (25922),；Table staphylococcus,
Middle staphylococcus, dissolving staphylococcal bacteria, Bacillus alcaligenes, very become bacillus, acinetobacter calcoaceticus, group B streptococcus, staphylococcus aureus (mark
Accurate), Hough Leah bacillus, Bacillus proteus, the abnormal bacillus of plate, citric acid enterobacteria, staphylococcus hominis and gastritis diplococcus, clinical point
From bacterial strain.
(4) animal: KM kind white mice, body weight 18～21g；SD rat, 173～212g；Rabbit, 2.3～2.5kg, male and female
Half and half.
(5) reagent: dimethylbenzene；Glacial acetic acid；Endotoxin；Dry yeast.
2, test method and result
Test according to content as described below respectively.Quantitative response data represent with mean+SD, qualitative response
Data represent with percentage rate, are respectively adopted t inspection, X2Inspection carries out statistical procedures.
(1) antibacterial action
1. the protective effect to infection of staphylococcus aureus mice
Take KM kind mice 120, be randomly divided into 6 groups, often group 20.Respectively organize the dosage gastric infusion 30ml/ as shown in table 1
Kg, every day 1 time, continuous 6 days, Normal group, model group gavage equal-volume distilled water.60min after being administered for 3rd day, except normal
Outside matched group, (bacteria containing amount is 1 LD to lumbar injection staphylococcus aureus culture fluid50) 0.5ml/ only, observe zoogenetic infection and
Morbidity after administration and death condition, the death toll in recording 7 days.The results detailed in Table 1.
Table 1 to the protective effect of infection of staphylococcus aureus mice (N=20)
Note: compare with model group: * p ＜ 0.05, * * p ＜ 0.01, * * * p ＜ 0.001.
As it can be seen from table 1 three dosage of pharmaceutical composition of the present invention all can improve Staphylococcus aureus to some extent
The survival rate of bacterium infecting mouse, but not statistically significant, extend the time-to-live of infection of staphylococcus aureus mice, wherein,
The effect of pharmaceutical composition high dose group of the present invention is obvious, compares with model group, has significant difference (p ＜ 0.05).
2. test result indicate that of brief summary table 1, pharmaceutical composition of the present invention has certain antibacterial action.
(3) antiinflammatory action
1. Dichlorodiphenyl Acetate causes the impact that mice capillary permeability increases
Take KM kind mice 50, be randomly divided into 5 groups, often group 10.Respectively organize the dosage gastric infusion 18ml/ as shown in table 2
Kg, every day 1 time, continuous 4 days, model group gavage equal-volume distilled water.45min, tail vein injection 0.5% Yi Wen after last administration
Thinking blue normal saline solution 0.1ml/10g, accompany lumbar injection 0.6% acetic acid 0.1ml/10g, after 20min, puts to death mice, beats
Opening abdominal cavity, repeatedly rinse abdominal cavity three times with 5ml normal saline, collect cleaning mixture, 1000rpm is centrifuged 5min, uv-spectrophotometric
Trap (OD value) is measured at meter 590nm.The results detailed in Table 2.
Table 2 Dichlorodiphenyl Acetate cause mice capillary permeability increase impact (N=20)
| Group | Dosage (g/kg) | Trap (OD value) |
| Model | 0.219±0.049 | |
| Aspirin | 0.6 | 0.133±0.042** |
| High dose of the present invention | 8 | 0.142±0.041** |
| Dosage in the present invention | 4 | 0.149±0.072* |
| Low dosage of the present invention | 2 | 0.171±0.083 |
Note: compare with model group: * p ＜ 0.05, * * p ＜ 0.01, * * * p ＜ 0.001.
From table 2 it can be seen that three dosage of medicine of the present invention all can reduce the mice capillary that acetic acid causes to some extent
Vascular permeability increases, and wherein the effect of the middle and high dosage of the present composition is obvious, compares with model group, has significance or pole
Significant difference (p ＜ 0.05 or p ＜ 0.01).
2. xylol causes the antiinflammatory action of mice ear
Take KM kind mice 50, be randomly divided into 5 groups, often group 10.Respectively organize the dosage gastric infusion 20ml/ as shown in table 3
Kg, every day 1 time, for three days on end, model group gavage equal-volume distilled water.45min after last administration, mouse right ear two topcoating diformazan
Only, left ear is not coated with benzene 0.05ml/.Put to death mice after 45min, lay disk in ears same area respectively, weigh, calculate swelling
Degree (=auris dextra weight-left ear weight), inhibitory rate of intumesce [=(model group swelling average-administration group swelling average)/model
Group swelling average × 100%].The results detailed in Table 3.
Table 3 xylol cause mice ear antiinflammatory action (N=20)
| Group | Dosage (g/kg) | Auricle swelling degree (mg) | Inhibitory rate of intumesce (%) |
| Model | - | 0.0197 scholar 0.0053 | - |
| Aspirin | 0.6 | 0.0068 scholar 0.0033*** | 65.48 |
| Embodiment 1 high dose | 8 | 0.0071 scholar 0.0059** | 63.95 |
| Dosage in embodiment 1 | 4 | 0.0097 scholar 0.0055* | 50.76 |
| Embodiment 1 low dosage | 2 | 0.0121 scholar 0.0043 | 38.58 |
Note: compare with model group: * p ＜ 0.05, * * p ＜ 0.01, * * * p ＜ 0.001.
From table 3 it can be seen that three dosage of medicine of the present invention all can reduce the mouse ear that dimethylbenzene causes to some extent
Swelling, wherein, the effect of middle and high dosage is obvious, compares with model group, has significance or pole significant difference (p ＜ 0.05 or p
＜ 0.01).
3. test result indicate that of brief summary table 2～3, chemical substance is stimulated the inflammation caused anti-by pharmaceutical composition of the present invention
Should have certain antagonism.
(4) analgesic activity
1. Dichlorodiphenyl Acetate causes the impact of mice pain
Take KM kind mice 50, be randomly divided into 5 groups, often group 10.Respectively organize the dosage gastric infusion 20ml/ as shown in table 4
Kg, model group gavage equal-volume distilled water.45min after administration, lumbar injection 0.6% acetum 0.1ml/10g, observe injection
The writhing response number of times (abdominal part indent, stretching, extension hind leg, buttocks are raised) that rear 15min occurs, calculates analgesia percentage rate [=(model
Group writhing number of times average-administration group writhing number of times average)/model group writhing number of times average × 100%].The results detailed in Table 4.
Table 4 Dichlorodiphenyl Acetate cause mice pain impact (N=20)
| Group | Dosage (g/kg) | Writhing number of times | Analgesia percentage rate (%) |
| Model | - | 37.9 scholar 6.2 | - |
| Tramadol hydrochloride | 0.131 | 21.3 soil 9.1* | 43.79 |
| High dose of the present invention | 8 | 21.7 scholar 9.3 | 42.74 |
| Dosage in the present invention | 4 | 23.9 scholar 9.1 | 36.93 |
| Low dosage of the present invention | 2 | 25.3 soil 9.2 | 33.25 |
Note: compare with model group: * p ＜ 0.05, * * p ＜ 0.01, * * * p ＜ 0.001.
From table 4, it can be seen that three dosage of pharmaceutical composition of the present invention all can reduce acetic acid induced pain mice to some extent
Writhing number of times.
2. test result indicate that of brief summary table 4, chemical substance is stimulated by pharmaceutical composition of the present invention has certain analgesia to make
With.
(5) safety analysis and evaluation
Taking mice 20, male and female half and half, body weight 20-22g, fasting (can't help water) 12h before experiment, every Mus is administered body by maximum
Long-pending (0.4ml/10g) gavage maximum can the concentrated solution of the present invention of gavage concentration (0.6g/ml), and within Yu Yi continuous 3 times,
Every minor tick 8h, Continuous Observation 7 days, have no that animal occurs death, after the first gavage of mice, see that animal activity reduces, in calmness
Shape, after general 3-4h, activity gradually recovers, after the 7th day mouse weights put to death, dissect, do not have seen from naked eyes have obvious liver, the heart, spleen,
Lung, the exception of kidney, it is 20.0 ± 0.8g that mice starts body weight, and within the 7th day, body weight is 22.3 ± 1.6g.Its every day of accumulation maximum tolerance
Amount is 67g/kg, and this amount has substantially exceeded quantity, it is believed that clinical practice totally nontoxic.
Conclusion (of pressure testing):
Being confirmed by pharmacological testing, pharmaceutical composition of the present invention has the effect that 1, to Staphylococcus aureus
Bacterium infecting mouse has significantly sterilization or inhibitory action；2, the mice capillary permeability increase that acetic acid causes is reduced；3、
Reduce the mice ear that dimethylbenzene causes；Reduce the writhing number of times of acetic acid induced pain mice, point out pharmaceutical composition of the present invention to have
There are the effects such as sterilization, antiinflammatory, analgesia.By acute toxicity test, long term toxicity test result shows: nothing under this experiment condition
Significantly toxic reaction.Compared with existing commercial preparation, effect of the present invention is obvious, rapid-action, has no side effect.
Two, clinical trial
1, physical data:
Inventor collects the out-patient of 900 example chronic atrophic gastritis, age altogether between in February ,-2013 in June, 2009
42-54 year, course of disease 1-5.It is randomly divided into 9 groups, takes the pharmaceutical composition of embodiment of the present invention 1-9 respectively, respectively organize age, disease
The data such as feelings there was no significant difference, and has comparability.
2, diagnostic criteria:
The symptom of chronic atrophic gastritis, sign are without specificity, it is impossible to as the foundation of diagnosis, make a definite diagnosis mainly by gastroscope and
Gastric mucosa living tissue pathologic finding.
(1) age: many above middle age, the course of disease is long, often has chronic superficial gastritis medical history.
(2) symptom and sign: long-term ingestion is bad, gastral cavilty portion distension is uncomfortable, poor appetite, weak, become thin, anemia etc..
(3) gastroscopy
1. gastric mucosa color is thin out；
2. under mucosa, blood vessel sees through；
3. duplicature is tiny even disappears；
4., when atrophic gastritis is with body of gland cervical region hyperplasia or intestinal epithelial metaplasia, mucous membrane surface is rough, in
Graininess or nodositas, visible pseudopolyp is formed sometimes, and under mucosa, the feature of exposed vessel is often blanked；
5. atrophy mucosa fragility increases, the most hemorrhage, and can have rotten to the corn stove；
6. atrophic gastritis such as congested erythema, can adhere to mucus simultaneously with the performance of chronic superficial gastritis, and instead
Light enhancing etc..
(4) pathologic finding
1. intrinsic in gastric mucosa body of gland atrophy；
2. metaplasia；
3. hypertrophy；
4. canceration.
(5) lab testing
1. the many anacidities of gastric analysis A type CAG patient or low acid, Type B CAG patient can normal or low acid；
2. pepsinogen measures pepsin reason cell secretes, pepsin during atrophic gastritis, in blood and urine
Proenzyme content reduces；
3. the G emiocytosis gastrin of serum gastrin determination gastric antrum portion mucosa.
A type CAG patient, serum gastrin Chang Mingxian increases；Type B CAG patient's Antral atrophy, directly affects G cell
Secretion gastrin function, serum gastrin is less than normal；
4. immunologic test parietal cell antibody (PCA), intrinsic factor antibody (IFA), gastrin secretion cell antibody (GCA) are surveyed
Fixed, can diagnose as the auxiliary of atrophic gastritis and typing thereof.
3, test method
Treatment group is administered orally the pharmaceutical composition that the present invention prepares, a 5g according to specific embodiment 1-9, one day three times, treats
Journey 10 days.
4, criterion of therapeutical effect
Effective: clinical symptoms all disappears, test chamber checks normal.
Effective: clinical symptom relief, the state of an illness is controlled, and lab testing improves or normal.
Invalid: clinical symptoms is without being clearly better or increasing the weight of.
5, treatment statistical result: be shown in Table 1.
Table 1 curative effect statistical table
| Group | Effective | Effectively | Invalid | Add up to | Effective percentage (%) |
| Embodiment 1 | 92 | 7 | 1 | 100 | 99 |
| Embodiment 2 | 90 | 8 | 2 | 100 | 98 |
| Embodiment 3 | 93 | 5 | 2 | 100 | 98 |
| Embodiment 4 | 92 | 4 | 4 | 100 | 96 |
| Embodiment 5 | 95 | 4 | 1 | 100 | 99 |
| Embodiment 6 | 97 | 2 | 1 | 100 | 99 |
| Embodiment 7 | 94 | 4 | 2 | 100 | 98 |
| Embodiment 8 | 93 | 4 | 3 | 100 | 97 |
| Embodiment 9 | 91 | 5 | 4 | 100 | 96 |
Treatment gastritis sufferer 900 example, total effective rate reaches 98%, and effect is obvious, and does not finds that untoward reaction is made with poison pair
With, illustrate that pharmaceutical composition of the present invention is evident in efficacy in terms for the treatment of gastritis, there is good promotional value.
In sum: pharmaceutical composition of the present invention has the effect that 1, little to infection of staphylococcus aureus
Mus has significantly sterilization or inhibitory action；2, the mice capillary permeability increase that acetic acid causes is reduced；3, diformazan is reduced
The mice ear that benzene causes；Reduce the writhing number of times of acetic acid induced pain mice, point out pharmaceutical composition of the present invention to have sterilization, resist
The effects such as inflammation, analgesia.By acute toxicity test, long term toxicity test result shows: without significantly poison under this experiment condition
Property reaction.Compared with existing commercial preparation, effect of the present invention is obvious, rapid-action, has no side effect；Stomach is treated by clinical trial
Scorching patient 900 example, total effective rate reaches 98%, and effect is obvious, and does not finds untoward reaction and toxic and side effects, and medicine of the present invention is described
Compositions is evident in efficacy in terms for the treatment of gastritis, has good promotional value.
Although, used general explanation, detailed description of the invention and test, the present invention made detailed retouching
Stating, but on the basis of the present invention, it can be made some amendments or improve, this is aobvious and easy to those skilled in the art
See.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (10)
1. the pharmaceutical composition treating gastritis, it is characterised in that this pharmaceutical composition is made up of the medicine of following weight portion:
Semen Iridis 20-60 part, Chinese honey locust (fruit) 10-50 part, Fructus Gleditsiae Abnormalis 10-45 part, Dioscorea septemloba Thunb. 15-60 part, Herba Siegesbeckiae 10-55 part, Rhizoma Bolbostematis
10-45 part, Radix Serratulae Chinensis 10-55 part, Folium Symplocoris Caudatae 12-45 part, Radix Isatidis 10-45 part, hieracioides 15-50 part, Cortex Phellodendri 20-70 part,
Radix Glycyrrhizae 20-60 part.
Pharmaceutical composition the most according to claim 1, it is characterised in that this pharmaceutical composition is by the medicine of following weight portion
Make: Semen Iridis 25-55 part, Chinese honey locust (fruit) 15-45 part, Fructus Gleditsiae Abnormalis 15-40 part, Dioscorea septemloba Thunb. 20-55 part, Herba Siegesbeckiae 15-50 part, soil
Bulbus Fritillariae Uninbracteatae 15-40 part, Radix Serratulae Chinensis 15-50 part, Folium Symplocoris Caudatae 15-42 part, Radix Isatidis 15-40 part, hieracioides 20-45 part, Cortex Phellodendri 25-65
Part, Radix Glycyrrhizae 25-55 part.
Pharmaceutical composition the most according to claim 2, it is characterised in that this pharmaceutical composition is by the medicine of following weight portion
Make: Semen Iridis 30-50 part, Chinese honey locust (fruit) 20-40 part, Fructus Gleditsiae Abnormalis 20-35 part, Dioscorea septemloba Thunb. 28-47 part, Herba Siegesbeckiae 20-45 part, soil
Bulbus Fritillariae Uninbracteatae 20-35 part, Radix Serratulae Chinensis 20-45 part, Folium Symplocoris Caudatae 20-37 part, Radix Isatidis 20-35 part, hieracioides 25-40 part, Cortex Phellodendri 33-57
Part, Radix Glycyrrhizae 30-50 part.
Pharmaceutical composition the most according to claim 3, it is characterised in that this pharmaceutical composition is by the medicine of following weight portion
Make: Semen Iridis 35-45 part, Chinese honey locust (fruit) 25-35 part, Fructus Gleditsiae Abnormalis 23-32 part, Dioscorea septemloba Thunb. 33-42 part, Herba Siegesbeckiae 25-40 part, soil
Bulbus Fritillariae Uninbracteatae 23-32 part, Radix Serratulae Chinensis 26-39 part, Folium Symplocoris Caudatae 23-33 part, Radix Isatidis 23-32 part, hieracioides 29-37 part, Cortex Phellodendri 40-50
Part, Radix Glycyrrhizae 35-45 part.
Pharmaceutical composition the most according to claim 4, it is characterised in that this pharmaceutical composition is by the medicine of following weight portion
Make: Semen Iridis 40 parts, Chinese honey locust (fruit) 30 parts, Fructus Gleditsiae Abnormalis 28 parts, Dioscorea septemloba Thunb. 38 parts, Herba Siegesbeckiae 32 parts, Rhizoma Bolbostematis 27 parts, Radix Serratulae Chinensis
32 parts, Folium Symplocoris Caudatae 28 parts, Radix Isatidis 28 parts, hieracioides 33 parts, Cortex Phellodendri 45 parts, 40 parts of Radix Glycyrrhizae.
6. according to the pharmaceutical composition described in any one of claim 1-5, it is characterised in that this pharmaceutical composition is possibly together with pharmacy
Upper acceptable carrier or diluent.
Pharmaceutical composition the most according to claim 6, it is characterised in that described pharmaceutical composition is solid preparation or liquid
Preparation, described solid preparation is tablet, capsule, granule or pill；Described liquid preparation is oral liquid.
8. the method for the pharmaceutical composition prepared described in any one of claim 1-5, it is characterised in that the method include with
Lower step: by Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae, Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, wind hair
Chrysanthemum, Cortex Phellodendri, Radix Glycyrrhizae pulverize and sieve, and mix homogeneously with pharmaceutically acceptable carrier or diluent, are prepared as preparation.
9. prepare the method for pharmaceutical composition described in any one of claim 1-5 for one kind, it is characterised in that the method includes following
Step:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae are added the heating of 3-7 times amount water and decoct 1-3 hour, filter, filter
Liquid concentrate drying, is ground into fine powder standby；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae add the water of 2-5 times amount, and it is little that heating decocts 2
Time, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds soak with ethanol 8-13 hour of 2-5 times amount 75%, mistake
Filter, filtrate concentrate drying, it is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add pharmaceutically acceptable carrier or diluent mix homogeneously, make preparation.
Pharmaceutical composition preparation method the most according to claim 9, it is characterised in that the method comprises the following steps:
1) weight portion medicine is weighed standby；
2) Semen Iridis, Chinese honey locust (fruit), Fructus Gleditsiae Abnormalis, Dioscorea septemloba Thunb., Herba Siegesbeckiae being added 5 times amount water heating and decocted 2 hours, filter, filtrate is dense
It is standby that contracting dry, pulverize into fine powder；
3) Rhizoma Bolbostematis, Radix Serratulae Chinensis, Folium Symplocoris Caudatae, Radix Isatidis, hieracioides, Cortex Phellodendri, Radix Glycyrrhizae add the water of 3 times amount, and it is little that heating decocts 2
Time, filter, filtrate concentrate drying, be ground into fine powder, standby；Filtering residue adds the soak with ethanol 10 hours of 3 times amount 75%, filters, filter
Liquid concentrate drying, is ground into fine powder, standby.
4) by above-mentioned fine powder mix homogeneously, add pharmaceutically acceptable carrier or diluent mix homogeneously, make preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610821322.1A CN106237023A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition treating gastritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610821322.1A CN106237023A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition treating gastritis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106237023A true CN106237023A (en) | 2016-12-21 |
Family
ID=57599763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610821322.1A Pending CN106237023A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition treating gastritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106237023A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013917A (en) * | 2014-06-23 | 2014-09-03 | 王家玲 | Traditional Chinese medicament for treating chronic gastritis |
| CN104491816A (en) * | 2014-12-30 | 2015-04-08 | 陈满锦 | Application of traditional Chinese medicinal composition in preparation of medicine for treating chronic gastroenteritis |
| CN105616921A (en) * | 2016-01-20 | 2016-06-01 | 张俊志 | Traditional Chinese medicine composition for treating upper respiratory tract infection and preparation method thereof |
-
2016
- 2016-08-30 CN CN201610821322.1A patent/CN106237023A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013917A (en) * | 2014-06-23 | 2014-09-03 | 王家玲 | Traditional Chinese medicament for treating chronic gastritis |
| CN104491816A (en) * | 2014-12-30 | 2015-04-08 | 陈满锦 | Application of traditional Chinese medicinal composition in preparation of medicine for treating chronic gastroenteritis |
| CN105616921A (en) * | 2016-01-20 | 2016-06-01 | 张俊志 | Traditional Chinese medicine composition for treating upper respiratory tract infection and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘绍能等: "《慢性胃炎中西医诊治180则》", 30 June 2014, 金盾出版社 * |
| 南京中医药大学: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 曾晓虎: "《中西汇通中药手册》", 31 May 2006, 人民军医出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101306180B (en) | Gastropathy treating medicine | |
| CN103735865A (en) | Medicine for preventing and treating exaggerated pain after anesthesia | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN105770679A (en) | Chinese herbal mouthwash for treating fungal infection of oral cavity | |
| CN106237023A (en) | A kind of pharmaceutical composition treating gastritis and preparation method thereof | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN105147802B (en) | Treat the composition and preparation method of porcine mycoplasmal, pig pleuropneumonia | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN107744554A (en) | A kind of pharyngitis mouth-sucking tablet and preparation method thereof | |
| CN106266308A (en) | A kind of pharmaceutical composition treating pneumonia and preparation method thereof | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN103120727B (en) | Traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN109833373A (en) | A kind of enema for treating hand foot and mouth disease | |
| CN102688306B (en) | Ointment for treating acute pancreatitis | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN103816327B (en) | One treats ileac Chinese medicine composition and preparation method thereof | |
| CN106266705A (en) | A kind of pharmaceutical composition treating gout | |
| CN103110737B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN106620294A (en) | Pharmaceutical composition for treating intestinal obstruction, and preparation method of pharmaceutical composition | |
| CN101167800A (en) | 'Shuanglian' injection and preparation process thereof | |
| CN107260749B (en) | Drug, pharmaceutical composition and the application for treating sleep apnea syndrome | |
| CN101904830B (en) | Application of citral in preparation of medicament for treating biliary tract diseases | |
| CN104083673A (en) | Traditional Chinese medicine composition for treating chronic glomerulonephritis and application of traditional Chinese medicine composition | |
| CN103735866A (en) | Capsules for preventing and treating exaggerative pain after anesthesia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190203 Address after: 271100 Zhai Li Central Health Center, Zhai Li Town, Laiwu City, Shandong Province Applicant after: Zhu Yingfu Address before: 264504 14, Lou Shan, Silver Beach, Rushan, Shandong. Applicant before: Lin Haiyan |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |
|
| RJ01 | Rejection of invention patent application after publication |